Vascular Perfusion to advance organ transportation through ULiSSES device

Vascular Perfusion Solutions has developed ULiSSES, a new self-contained medical device for organs and limbs transportation, extending the timeframe for organ and limb feasibility.

ULiSSES, which stands for Universal Limb/Organ Stasis System for Extended Storage, is a portable and easy to use device for organ and limb transport, which uses oxygen to preserve and resuscitate vascularized tissue — organs and limbs — for over 24-hours, compared to only 4 to 6 hours with existing systems.

Leonid Bunegin – chief scientific officer, Vascular Perfusion Solutions said: “Our ULiSSES device is designed to be portable, affordable, and easy to use, which makes it more accessible to more hospitals, doctors, and most importantly, transplant patients.”

Licensed by the University of Texas Health Science Center at San Antonio, ULiSSES is transported in a commercial airliner and stored in an overhead compartment or under the seat.

The device designed by the San Antonio-based Vascular Perfusion Solutions team can also operate as a bioreactor to grow new skin for burn victims.

ULiSSES device from Vascular Perfusion Solutions. Photo courtesy of Business Wire.

Successfully tested in small animals, the ULiSSES is set for study in large animals to pave way for human testing.

With animal testing to be conducted by the U.S. Army’s Institute of Surgical Research, the company is working with the University of Texas Health Science Center at San Antonio, the University of Texas at San Antonio, Harvard Medical School, Massachusetts General Hospital, and the U.S. Department of Defense.

Vascular Perfusion Solutions is currently working to advance ULiSSES device through FDA clearance and to get into early clinical use.

The medical devices company received a Joint Warfighter Medical Research grant from the U.S. Department of Defense in support of this additional work.

Related posts

• Catabasis’ PolarisDMD clinical trial for edasalonexent completes enrollment (0)
• Sobi to acquire US pharma company Dova Pharmaceuticals in $915m deal (0)
• Meissa Vaccines raises $30m to move RSV Vaccine into clinical trials (0)
• Progenity buys assets of ingestible device company Medimetrics (0)
• Constellation doses first patient in phase 1 trial of CPI-0209 for cancer (0)
• Amphivena Therapeutics raises $62m to advance AMV564 into solid tumors (0)
• Annexon gets FDA fast track status for ANX005 in Guillain-Barré Syndrome (0)
• Opentrons launches fully automated thermocycler at $4,000 (0)
• Avior Bio to advance kidney disease treatment through Sono-Tek ultrasonic coating equipment (0)
• CinDome Pharma begins phase 2 trial of gastroparesis drug CIN-102 (0)

The post Vascular Perfusion to advance organ transportation through ULiSSES device appeared first on PharmaNewsDaily.com.